<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01652703</url>
  </required_header>
  <id_info>
    <org_study_id>20110231</org_study_id>
    <nct_id>NCT01652703</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects</brief_title>
  <acronym>AMG145</acronym>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Combination With Stable Statin Therapy in Japanese Subjects With Hypercholesterolemia and High Cardiovascular Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the effect of 12 weeks of subcutaneous evolocumab every
      2 weeks or every 4 weeks, compared with placebo, on percent change from baseline in
      low-density lipoprotein cholesterol (LDL-C) when used in addition to statin therapy in
      Japanese adults with hypercholesterolemia and high cardiovascular risk.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>LDL-C was measured using ultracentrifugation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>LDL-C was measured using ultracentrifugation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an LDL-C Response at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>An LDL-C response was defined as LDL-C &lt; 70 mg/dL (1.8 mmol/L) at Week 12. LDL-C was measured using ultracentrifugation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Non-HDL-C</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Apolipoprotein B</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in VLDL-C</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Total Cholesterol/HDL-C Ratio</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Apolipoprotein B/Apolipoprotein A-1 Ratio</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">310</enrollment>
  <condition>Hypercholesterolemia and High Risk for Cardiovascular Events</condition>
  <arm_group>
    <arm_group_label>Placebo Q2W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Q4W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab 70 mg Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab 140 mg Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab 280 mg Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab 420 mg Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Evolocumab</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>Evolocumab 70 mg Q2W</arm_group_label>
    <arm_group_label>Evolocumab 140 mg Q2W</arm_group_label>
    <arm_group_label>Evolocumab 280 mg Q4W</arm_group_label>
    <arm_group_label>Evolocumab 420 mg Q4W</arm_group_label>
    <other_name>AMG 145</other_name>
    <other_name>Repatha</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>Placebo Q2W</arm_group_label>
    <arm_group_label>Placebo Q4W</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Japanese adult, on statin, with or without ezetimibe, with stable
        dose(s) for at least 4 weeks, fasting LDL-C greater than or equal to 115 mg/dL (3.0
        mmol/L), fasting triglycerides less than or equal to 400 mg/dL (4.5 mmol/L); Exclusion
        Criteria: New York Heart Association (NYHA) class III or IV, poorly controlled
        hypertension, recently diagnosed or poorly controlled type 2 diabetes, last known left
        ventricular ejection fraction &lt; 30%, myocardial infarction, unstable angina, percutaneous
        coronary intervention (PCI), coronary artery bypass graft (CABG), stroke, planned cardiac
        surgery or revascularization within 6 months of randomization, uncontrolled cardiac
        arrhythmia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>454-0933</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>455-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>462-0825</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukui-shi</city>
        <state>Fukui</state>
        <zip>910-0067</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukui-shi</city>
        <state>Fukui</state>
        <zip>910-0803</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukui-shi</city>
        <state>Fukui</state>
        <zip>910-0837</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kasuga-shi</city>
        <state>Fukuoka</state>
        <zip>816-0864</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gifu-shi</city>
        <state>Gifu</state>
        <zip>500-8384</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fujioka-shi</city>
        <state>Gunma</state>
        <zip>375-0015</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maebashi-shi</city>
        <state>Gunma</state>
        <zip>371-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maebashi-shi</city>
        <state>Gunma</state>
        <zip>371-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takasaki-shi</city>
        <state>Gunma</state>
        <zip>370-0829</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kawani-shi</city>
        <state>Hyogo</state>
        <zip>666-0125</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <zip>657-0068</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hitachi-shi</city>
        <state>Ibaraki</state>
        <zip>317-0077</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koga-shi</city>
        <state>Ibaraki</state>
        <zip>306-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mito-shi</city>
        <state>Ibaraki</state>
        <zip>311-4198</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Komatsu-shi</city>
        <state>Ishikawa</state>
        <zip>923-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takamatsu-shi</city>
        <state>Kagawa</state>
        <zip>760-8557</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kochi-shi</city>
        <state>Kochi</state>
        <zip>781-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kumamoto-shi</city>
        <state>Kumamoto</state>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto</state>
        <zip>613-0911</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto</state>
        <zip>615-8125</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ina-shi</city>
        <state>Nagano</state>
        <zip>396-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsumoto-shi</city>
        <state>Nagano</state>
        <zip>390-0848</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suwa-shi</city>
        <state>Nagano</state>
        <zip>392-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ibaraki-shi</city>
        <state>Osaka</state>
        <zip>567-0876</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toyonaka-shi</city>
        <state>Osaka</state>
        <zip>560-0082</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hanyu-shi</city>
        <state>Saitama</state>
        <zip>348-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sayama-shi</city>
        <state>Saitama</state>
        <zip>350-1305</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toda-shi</city>
        <state>Saitama</state>
        <zip>335-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Otsu-shi</city>
        <state>Shiga</state>
        <zip>520-0113</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8421</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>101-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hachioji-shi</city>
        <state>Tokyo</state>
        <zip>192-0918</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>141-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taito-ku</city>
        <state>Tokyo</state>
        <zip>111-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo</state>
        <zip>171-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Hirayama A, Honarpour N, Yoshida M, Yamashita S, Huang F, Wasserman SM, Teramoto T. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study. Circ J. 2014;78(5):1073-82. Epub 2014 Mar 21.</citation>
    <PMID>24662398</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2012</study_first_submitted>
  <study_first_submitted_qc>July 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2012</study_first_posted>
  <results_first_submitted>September 3, 2015</results_first_submitted>
  <results_first_submitted_qc>September 3, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 5, 2015</results_first_posted>
  <disposition_first_submitted>May 12, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>May 12, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 26, 2014</disposition_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese, hypercholesterolemia, high risk for cardiovascular events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Japanese men or women ≥ 20 to ≤ 80 years of age and who were at high risk for cardiovascular events, on a stable dose of an approved statin (with or without ezetimibe) and fasting low-density lipoprotein cholesterol (LDL-C) ≥ 115 mg/dL.
First patient enrolled on 10 July 2012; last patient enrolled 19 February 2013.</recruitment_details>
      <pre_assignment_details>Randomization was stratified by screening LDL-C level (&lt; 130 mg/dL [3.4 mmol/L] vs
≥ 130 mg/dL) and by diagnosis of heterozygous familial hypercholesterolemia (HeFH) (yes vs no).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Q2W</title>
          <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Q4W</title>
          <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Evolocumab 70 mg Q2W</title>
          <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Evolocumab 140 mg Q2W</title>
          <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Evolocumab 280 mg Q4W</title>
          <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Evolocumab 420 mg Q4W</title>
          <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="52"/>
                <participants group_id="P5" count="52"/>
                <participants group_id="P6" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="49"/>
                <participants group_id="P4" count="52"/>
                <participants group_id="P5" count="51"/>
                <participants group_id="P6" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="51"/>
                <participants group_id="P6" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (all randomized participants who received at least 1 dose of investigational product).</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Q2W</title>
          <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Q4W</title>
          <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Evolocumab 70 mg Q2W</title>
          <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Evolocumab 140 mg Q2W</title>
          <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Evolocumab 280 mg Q4W</title>
          <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Evolocumab 420 mg Q4W</title>
          <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="49"/>
            <count group_id="B4" value="52"/>
            <count group_id="B5" value="51"/>
            <count group_id="B6" value="53"/>
            <count group_id="B7" value="307"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.2" spread="10.1"/>
                    <measurement group_id="B2" value="60.9" spread="9.8"/>
                    <measurement group_id="B3" value="64.1" spread="9.7"/>
                    <measurement group_id="B4" value="60.8" spread="9.2"/>
                    <measurement group_id="B5" value="61.6" spread="9.6"/>
                    <measurement group_id="B6" value="61.3" spread="9.9"/>
                    <measurement group_id="B7" value="61.5" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="36"/>
                    <measurement group_id="B7" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="51"/>
                    <measurement group_id="B6" value="53"/>
                    <measurement group_id="B7" value="307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stratification Factor: LDL Level</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 130 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 130 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="36"/>
                    <measurement group_id="B6" value="36"/>
                    <measurement group_id="B7" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stratification Factor: Diagnosis of Heterozygous Familial Hypercholesterolemia (HeFH)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="47"/>
                    <measurement group_id="B6" value="49"/>
                    <measurement group_id="B7" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL-C Concentration</title>
          <description>LDL-C was measured using ultracentrifugation.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144.4" spread="18.1"/>
                    <measurement group_id="B2" value="141.8" spread="23.4"/>
                    <measurement group_id="B3" value="143.6" spread="20.6"/>
                    <measurement group_id="B4" value="140.7" spread="23.3"/>
                    <measurement group_id="B5" value="141.0" spread="21.2"/>
                    <measurement group_id="B6" value="139.7" spread="18.8"/>
                    <measurement group_id="B7" value="141.8" spread="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171.3" spread="23.0"/>
                    <measurement group_id="B2" value="168.7" spread="26.1"/>
                    <measurement group_id="B3" value="170.6" spread="27.2"/>
                    <measurement group_id="B4" value="166.3" spread="26.2"/>
                    <measurement group_id="B5" value="165.5" spread="24.4"/>
                    <measurement group_id="B6" value="166.7" spread="23.5"/>
                    <measurement group_id="B7" value="168.2" spread="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein B Concentration</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114.6" spread="15.4"/>
                    <measurement group_id="B2" value="112.5" spread="16.6"/>
                    <measurement group_id="B3" value="113.1" spread="19.2"/>
                    <measurement group_id="B4" value="109.4" spread="16.0"/>
                    <measurement group_id="B5" value="109.6" spread="16.9"/>
                    <measurement group_id="B6" value="109.8" spread="15.9"/>
                    <measurement group_id="B7" value="111.5" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Very Low-Density Lipoprotein Cholesterol (VLDL-C) Concentration</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.9" spread="10.5"/>
                    <measurement group_id="B2" value="27.1" spread="10.7"/>
                    <measurement group_id="B3" value="26.9" spread="13.3"/>
                    <measurement group_id="B4" value="25.6" spread="10.8"/>
                    <measurement group_id="B5" value="24.6" spread="10.5"/>
                    <measurement group_id="B6" value="27.0" spread="12.0"/>
                    <measurement group_id="B7" value="26.4" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol/HDL-C Ratio</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.380" spread="0.949"/>
                    <measurement group_id="B2" value="4.317" spread="1.075"/>
                    <measurement group_id="B3" value="4.366" spread="1.177"/>
                    <measurement group_id="B4" value="4.302" spread="1.039"/>
                    <measurement group_id="B5" value="4.228" spread="0.993"/>
                    <measurement group_id="B6" value="4.210" spread="0.955"/>
                    <measurement group_id="B7" value="4.300" spread="1.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein B/Apolipoprotein A-1 Ratio</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.750" spread="0.150"/>
                    <measurement group_id="B2" value="0.741" spread="0.177"/>
                    <measurement group_id="B3" value="0.743" spread="0.177"/>
                    <measurement group_id="B4" value="0.722" spread="0.163"/>
                    <measurement group_id="B5" value="0.725" spread="0.151"/>
                    <measurement group_id="B6" value="0.714" spread="0.158"/>
                    <measurement group_id="B7" value="0.732" spread="0.162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
        <description>LDL-C was measured using ultracentrifugation.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; missing ultracentrifugation (UC) LDL-C at Week 12 was imputed using last observation carried forward (LOCF) and calculated LDL-C.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q4W</title>
            <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab 70 mg Q2W</title>
            <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab 280 mg Q4W</title>
            <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab 420 mg Q4W</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
          <description>LDL-C was measured using ultracentrifugation.</description>
          <population>Full analysis set; missing ultracentrifugation (UC) LDL-C at Week 12 was imputed using last observation carried forward (LOCF) and calculated LDL-C.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.71" spread="2.16"/>
                    <measurement group_id="O2" value="0.05" spread="2.32"/>
                    <measurement group_id="O3" value="-55.56" spread="2.23"/>
                    <measurement group_id="O4" value="-71.32" spread="2.16"/>
                    <measurement group_id="O5" value="-58.10" spread="2.33"/>
                    <measurement group_id="O6" value="-63.89" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-68.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.99</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-74.51</ci_lower_limit>
            <ci_upper_limit>-62.71</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-52.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.84</ci_lower_limit>
            <ci_upper_limit>-46.86</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-63.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-70.23</ci_lower_limit>
            <ci_upper_limit>-57.66</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and placebo, and the alternative hypothesis was that a mean difference did exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-58.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-64.51</ci_lower_limit>
            <ci_upper_limit>-51.81</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
        <description>LDL-C was measured using ultracentrifugation.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; missing data were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q4W</title>
            <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab 70 mg Q2W</title>
            <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab 280 mg Q4W</title>
            <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab 420 mg Q4W</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
          <description>LDL-C was measured using ultracentrifugation.</description>
          <population>Full analysis set; missing data were imputed using LOCF.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="3.6"/>
                    <measurement group_id="O2" value="0.8" spread="3.4"/>
                    <measurement group_id="O3" value="-77.2" spread="3.7"/>
                    <measurement group_id="O4" value="-98.0" spread="3.6"/>
                    <measurement group_id="O5" value="-79.9" spread="3.4"/>
                    <measurement group_id="O6" value="-87.4" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-96.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-106.0</ci_lower_limit>
            <ci_upper_limit>-86.5</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-75.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-85.4</ci_lower_limit>
            <ci_upper_limit>-65.5</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-88.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-97.4</ci_lower_limit>
            <ci_upper_limit>-79.0</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-80.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-90.0</ci_lower_limit>
            <ci_upper_limit>-71.4</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an LDL-C Response at Week 12</title>
        <description>An LDL-C response was defined as LDL-C &lt; 70 mg/dL (1.8 mmol/L) at Week 12. LDL-C was measured using ultracentrifugation.</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q4W</title>
            <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab 70 mg Q2W</title>
            <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab 280 mg Q4W</title>
            <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab 420 mg Q4W</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an LDL-C Response at Week 12</title>
          <description>An LDL-C response was defined as LDL-C &lt; 70 mg/dL (1.8 mmol/L) at Week 12. LDL-C was measured using ultracentrifugation.</description>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="3.6"/>
                    <measurement group_id="O2" value="0.0" spread="3.4"/>
                    <measurement group_id="O3" value="66.0" spread="3.7"/>
                    <measurement group_id="O4" value="96.0" spread="3.6"/>
                    <measurement group_id="O5" value="80.4" spread="3.4"/>
                    <measurement group_id="O6" value="82.4" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Logistic Regression model includes treatment arms in dose frequency of Q2W and stratification factor of screening LDL-C level.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1945.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.64</ci_lower_limit>
            <ci_upper_limit>42232.63</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Logistic Regression model includes treatment arms in dose frequency of Q2W and stratification factor of screening LDL-C level.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>281.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.74</ci_lower_limit>
            <ci_upper_limit>5360.92</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Logistic Regression model includes treatment arms in dose frequency of Q4W and stratification factor of screening LDL-C level.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>536.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>28.37</ci_lower_limit>
            <ci_upper_limit>10143.40</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Logistic Regression model includes treatment arms in dose frequency of Q4W and stratification factor of screening LDL-C level.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>595.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>31.11</ci_lower_limit>
            <ci_upper_limit>11402.67</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Non-HDL-C</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; missing data were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q4W</title>
            <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab 70 mg Q2W</title>
            <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab 280 mg Q4W</title>
            <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab 420 mg Q4W</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Non-HDL-C</title>
          <population>Full analysis set; missing data were imputed using LOCF.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.20" spread="1.94"/>
                    <measurement group_id="O2" value="0.55" spread="2.17"/>
                    <measurement group_id="O3" value="-51.66" spread="2.00"/>
                    <measurement group_id="O4" value="-64.76" spread="1.94"/>
                    <measurement group_id="O5" value="-53.00" spread="2.17"/>
                    <measurement group_id="O6" value="-57.53" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-62.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.68</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-67.85</ci_lower_limit>
            <ci_upper_limit>-57.27</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-49.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.72</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.83</ci_lower_limit>
            <ci_upper_limit>-44.08</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-58.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.96</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-63.93</ci_lower_limit>
            <ci_upper_limit>-52.22</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-53.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.99</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-59.46</ci_lower_limit>
            <ci_upper_limit>-47.63</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Apolipoprotein B</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; missing data were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q4W</title>
            <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab 70 mg Q2W</title>
            <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab 280 mg Q4W</title>
            <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab 420 mg Q4W</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Apolipoprotein B</title>
          <population>Full analysis set; missing data were imputed using LOCF.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.90" spread="1.82"/>
                    <measurement group_id="O2" value="0.22" spread="2.02"/>
                    <measurement group_id="O3" value="-47.65" spread="1.88"/>
                    <measurement group_id="O4" value="-61.59" spread="1.82"/>
                    <measurement group_id="O5" value="-47.16" spread="2.03"/>
                    <measurement group_id="O6" value="-53.22" spread="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-60.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.67</ci_lower_limit>
            <ci_upper_limit>-55.72</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-46.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.80</ci_lower_limit>
            <ci_upper_limit>-41.70</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-53.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.77</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.91</ci_lower_limit>
            <ci_upper_limit>-47.97</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-47.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.80</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52.90</ci_lower_limit>
            <ci_upper_limit>-41.85</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in VLDL-C</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; missing data were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q4W</title>
            <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab 70 mg Q2W</title>
            <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab 280 mg Q4W</title>
            <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab 420 mg Q4W</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in VLDL-C</title>
          <population>Full analysis set; missing data were imputed using LOCF.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.23" spread="8.55"/>
                    <measurement group_id="O2" value="7.26" spread="6.87"/>
                    <measurement group_id="O3" value="-16.02" spread="8.74"/>
                    <measurement group_id="O4" value="-26.26" spread="8.44"/>
                    <measurement group_id="O5" value="-13.56" spread="6.80"/>
                    <measurement group_id="O6" value="-22.56" spread="6.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-34.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.75</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-57.71</ci_lower_limit>
            <ci_upper_limit>-11.26</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.044</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-24.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.93</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.83</ci_lower_limit>
            <ci_upper_limit>-0.68</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-29.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.32</ci_lower_limit>
            <ci_upper_limit>-11.32</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.028</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-20.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.41</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.41</ci_lower_limit>
            <ci_upper_limit>-2.22</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Total Cholesterol/HDL-C Ratio</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; missing data were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q4W</title>
            <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab 70 mg Q2W</title>
            <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab 280 mg Q4W</title>
            <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab 420 mg Q4W</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Total Cholesterol/HDL-C Ratio</title>
          <population>Full analysis set; missing data were imputed using LOCF.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.82" spread="1.91"/>
                    <measurement group_id="O2" value="1.19" spread="2.09"/>
                    <measurement group_id="O3" value="-42.04" spread="1.98"/>
                    <measurement group_id="O4" value="-51.81" spread="1.91"/>
                    <measurement group_id="O5" value="-44.11" spread="2.10"/>
                    <measurement group_id="O6" value="-45.47" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-46.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52.21</ci_lower_limit>
            <ci_upper_limit>-41.76</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-37.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.68</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.52</ci_lower_limit>
            <ci_upper_limit>-31.91</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-46.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52.32</ci_lower_limit>
            <ci_upper_limit>-41.00</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-45.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.89</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.02</ci_lower_limit>
            <ci_upper_limit>-39.58</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Apolipoprotein B/Apolipoprotein A-1 Ratio</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set; missing data were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Q2W</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Q4W</title>
            <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab 70 mg Q2W</title>
            <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab 140 mg Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Evolocumab 280 mg Q4W</title>
            <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Evolocumab 420 mg Q4W</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Apolipoprotein B/Apolipoprotein A-1 Ratio</title>
          <population>Full analysis set; missing data were imputed using LOCF.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.18" spread="2.12"/>
                    <measurement group_id="O2" value="1.44" spread="2.21"/>
                    <measurement group_id="O3" value="-50.71" spread="2.19"/>
                    <measurement group_id="O4" value="-64.53" spread="2.12"/>
                    <measurement group_id="O5" value="-50.79" spread="2.22"/>
                    <measurement group_id="O6" value="-56.31" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-61.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.93</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-67.14</ci_lower_limit>
            <ci_upper_limit>-55.56</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-47.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.98</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.41</ci_lower_limit>
            <ci_upper_limit>-41.65</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-57.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-63.73</ci_lower_limit>
            <ci_upper_limit>-51.77</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Testing based on a significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model included treatment group and stratification factor of screening LDL-C level.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-52.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.27</ci_lower_limit>
            <ci_upper_limit>-46.18</ci_upper_limit>
            <estimate_desc>Placebo is the reference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Q2W</title>
          <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Q4W</title>
          <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Evolocumab Q2W 70 MG</title>
          <description>Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Evolocumab Q2W 140 MG</title>
          <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Evolocumab Q4W 280 MG</title>
          <description>Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Evolocumab Q4W 420 MG</title>
          <description>Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Carcinoid tumour of the caecum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

